Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash from Investing Activities: 2016-2024

Historic Cash from Investing Activities for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to -$699,000.

  • Mereo BioPharma Group's Cash from Investing Activities was N/A to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$719,000, marking a year-over-year change of. This contributed to the annual value of -$699,000 for FY2024, which is 66.83% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Cash from Investing Activities stood at -$699,000 for FY2024, which was down 66.83% from -$419,000 recorded in FY2023.
  • Mereo BioPharma Group's 5-year Cash from Investing Activities high stood at $2.0 million for FY2022, and its period low was -$699,000 during FY2024.
  • Over the past 3 years, Mereo BioPharma Group's median Cash from Investing Activities value was -$419,000 (recorded in 2023), while the average stood at $289,667.
  • In the last 5 years, Mereo BioPharma Group's Cash from Investing Activities tumbled by 129.56% in 2021 and then spiked by 450.12% in 2022.
  • Over the past 5 years, Mereo BioPharma Group's Cash from Investing Activities (Yearly) stood at $1.9 million in 2020, then slumped by 129.56% to -$567,512 in 2021, then surged by 450.12% to $2.0 million in 2022, then plummeted by 121.09% to -$419,000 in 2023, then tumbled by 66.83% to -$699,000 in 2024.